News

A new triple-combination CFTR modulator therapy for cystic fibrosis (CF) — vanzacaftor, tezacaftor and deutivacaftor — outperformed the approved therapy Trikafta (elexacaftor/tezacaftor/ivacaftor) at reducing sweat chloride levels in Phase 3 trials. The new “vanza triple” combo was similar to Trikafta at maintaining…

An eight-week remote exercise program of moderate to high intensity increased leg muscle strength and reduced body fat in adults with cystic fibrosis (CF), a new study showed. While no differences were found in lung function and quality of life, the gains seen with the short-term duration of the exercise…

A pooled analysis of data from multiple clinical trials of more than 1,100 people with cystic fibrosis (CF) confirms Trikafta effectively improves lung function, sweat chloride levels, and health-related quality of life. “Further monitoring and assessment of the safety profile of [Trikafta]…

Treatment with Kaftrio (elexacaftor/tezacaftor/ivacaftor), sold in the U.S. as Trikafta, reduced signs of sinus disease, as seen on MRI scans, among children with cystic fibrosis (CF), according to new research from Germany. Improvements were seen on the children’s imaging scans regardless of whether they had never before used…

Enterprise Therapeutics has raised £26 million (nearly $33 million USD) in series B financing, which the company is planning to use to fund a Phase 2a clinical trial of EDT001, its experimental treatment for cystic fibrosis (CF). The upcoming trial is expected to enroll people with CF who…

Treatment with SPI-1005 in adults with cystic fibrosis (CF) appeared to lessen the risk of ear damage related to antibiotics use — widely prescribed for treating lung infections in CF patients — in a Phase 2 clinical trial. That’s according to new interim data from the STOP study…

Adults with cystic fibrosis (CF) make as much use of most routine preventive healthcare services as adults in the general population, and in some cases more than they do, according to a recent analysis of U.S. insurance claims data. This services — of growing importance as CFTR modulator…

Staying physically active, especially engaging in more vigorous exercise regularly, is important for lung health and life quality in adolescents and adults with cystic fibrosis (CF), a study reports. Better lung function and exercise capacity were key factors in a patient’s overall quality of life, the researchers found, adding…

The Cystic Fibrosis Foundation has announced new funding of up to $15 million to Prime Medicine to further develop its gene-editing technology — called Prime Editing — for cystic fibrosis (CF). The award is part of the foundation’s $500 million Path to a Cure initiative, which aims…

The first volunteer has been dosed in a Phase 1 clinical trial evaluating SION-109, an experimental oral treatment for cystic fibrosis (CF), as announced by Sionna Therapeutics, the therapy’s developer. After receiving the green light from the U.S. Food and Drug Administration, the trial has enrolled healthy volunteers to…